Journal of the American Academy of Dermatology

publisher

articletitle

journaltitle

articlelink

content_type

copyright

Pfizer

Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients

J Eur Acad Dermatol Venereol

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis

J Invest Dermatol

Lymphocytes, neuropeptides, and genes involved in alopecia areata

J Clin Invest

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

Nat Med

Two phase 3 trials of baricitinib for alopecia areata

N Engl J Med

Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study

J Am Acad Dermatol

A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata

Arch Dermatol Res

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients

Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19

Adv Ther

Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata

Dermatol Ther

Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort

Combination tofacitinib and oral minoxidil treatment for severe alopecia areata

Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.

Janus kinase inhibitors for alopecia areata.

Janus kinase inhibitors for alopecia areata

Papers